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Abstract Topiramate is known to be efficacious in
migraine prophylaxis, but its optimal dose has not been
systematically studied in the Asian population. Here, we
show that a fixed low dose of topiramate 25 mg/day is
efficacious in migraine prophylaxis and also attest to
advantages in terms of medication cost savings and more
favourable side effect profile.
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Introduction
Migraine is a common neurological illness worldwide
leading to significant effects on morbidity, productivity and
quality of life [1]. Prevention of migraine attacks is an
important clinical strategy.
The anticonvulsant topiramate is known in the Western
setting to be effective in migraine prevention [2–4]. These
previous studies, of which Asians form the minority, have
employed dosages at or above 100 mg/day for prophylaxis.
However, there is evidence that lower dosages of topira-
mate may be effective in migraine prevention, particularly
in the Asian population [5–7]. This may have important
clinical implications in terms of cost and side effects. To
our knowledge, three previous studies comprising Koreans,
Chinese and Indians, have addressed the use of topiramate
in the Asian patients [5–7]. Two studies had employed
dosages of at or above 50 mg/day [5, 6], while the third,
utilizing a variable titration method, had suggested that
daily dosages as low as 25 mg may be effective [7]. In
addition, two other studies involving Iranian patients have
utilized topiramate dosages up to 50 mg/day and concluded
it to be as effective as propanolol and sodium valproate in
migraine prophylaxis [8, 9], providing further evidence of
its efficacy in Asians. In this study, we sought to further
clarify dosage issues in a prospective dosing study of
migraine patients in the multiracial Asian setting.
Methods
With local ethical committee (Singapore General Hospital
Institutional Review Board) approval, we prospectively
screened 82 patients having migraine with or without aura,
as defined by the International Classification of Headache
Disorders 2nd Edition [10]. In particular, we had ensured
that patients included should have at least four headache
episodes in the preceding 4 weeks, with each episode at
least four of ten in severity on the visual analogue scale
(VAS). Otherwise, subjects were considered screen fail-
ures. Of these, 42 were excluded: 7 patients became un-
contactable prior to randomization, 23 were screen failures
and 12 had withdrawn consent during the study.
A total of 40 patients (age range 18–64, mean age 38, 30
females, 10 males) were randomized into the study. There
were 22 Chinese, 6 Malays, 8 Indians and 4 Eurasians.
Patients were recruited in a consecutive fashion from a
headache specialist clinic in a tertiary general hospital.
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Each was briefed upon randomization on how to record
symptoms and side effects into the headache diary.
Each patient had kept a headache diary 4 weeks prior to
randomization, documenting baseline migraine attacks
over this period. Patients documented frequency as the
number of days with headache in the preceding 4 weeks,
duration of the most severe attack in a day in hours, and
severity measured as the worst period during an attack on a
VAS from 0 to 10 cm. During the entire treatment period,
they were allowed symptomatic medications such as par-
acetamol, but triptans and opioids were disallowed. How-
ever, any prior use of prophylactic medication of any class
at any time documented was an exclusion criterion. We
excluded all subjects with history suggesting analgesic
overuse. This was defined as usage of triptans [3 days a
week, simple analgesics [4 days a week or narcotic anal-
gesics [2 days a week.
Each patient was randomized to receive 25, 50, 75 or
100 mg of topiramate as an evening dose, with 10 patients
in each arm. For the 50 mg arm, patients started on 25 mg
for 1 week before continuing with 50 mg for the rest of the
study. Similarly, for the 75 mg arm, patients started with
25 mg for 1 week, 50 mg for the second week, and 75 mg
for the subsequent weeks. The dose escalation was in a
similar manner for the 100 mg arm. The end-point of the
study was 12 weeks after achieving the intended topira-
mate dosage for that particular treatment arm, and patients
returned for follow-up every 4 weeks after starting treat-
ment. Comparisons were made between migraine attacks at
baseline and the 4-week period prior to the end-point
(Fig. 2). It should be noted that upward titration of dosages
were gradual and necessary to minimize side effects and
drop outs. For the 50, 75 and 100 mg arms, each patient















































Fig. 1 Overall headache parameters comparing baseline (time point 1) to study end-point (time point 2)
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dose of that particular arm before study end-point was
achieved.
Statistical calculations were performed with SPSS for
Windows package, employing the Wilcoxon Signed Rank,
Kruskal–Wallis and Pearson’s correlation tests. A p
value \ 0.05 was regarded as statistically significant.
Results
Of the 40 patients who had completed the trial, no signif-
icant differences in baseline headache frequency, duration
and severity was found between the four treatment arms.
Overall, we found that topiramate significantly reduced
headache frequency (headache days) comparing baseline to
end-point (Wilcoxon Signed Rank test, Z = -3.47,
p = 0.001). However, no significant differences were
found for headache duration (Wilcoxon Signed Rank test,
Z = -0.23, p = 0.82) or severity (Wilcoxon Signed Rank
test, Z = -0.31, p = 0.76).
In terms of side effects, paresthesia was by far the most
commonly encountered in 55% of patients. However, its
incidence was highly correlated with increasing dosage
(Pearson’s correlation, r = 0.96, p \ 0.001).
Figure 1 summarizes overall headache parameters
comparing baseline to study end-point. Figure 2 provides a
flow diagram of the study protocol. Side effects encoun-
tered are shown in Table 1. Table 2 depicts numerical data
of headache parameters.
Discussion
To our knowledge, this is the first fixed dose ranging study
designed specifically to address this issue employing a
simple and straightforward clinical approach. Here, we
Table 1 Summary of most common side effects in 40 patients
Side effect Dose (number of patients)
25 mg 50 mg 75 mg 100 mg
Paresthesia 4 5 6 7
Fatigue 1 1 3 2
Giddiness 1 2 1 1
Diarrhoea 3 0 0 1
Nausea 1 1 0 2
Drowsiness 1 1 2 0
Table 2 Summary of results of all recruited patients
Time Baseline Time 1 Time 2 Time 3
Frequency (days)
25 mg 10.2 (5.1) 7.6 (6.4) 3.5 (2.2) 4.1 (1.9)
50 mg 6.9 (2.6) 8.1 (4.2) 6.5 (4.8) 6.8 (5.7)
75 mg 8.8 (4.4) 6.2 (5.9) 5.8 (6.6) 3.3 (4.4)
100 mg 8.0 (2.5) 8.8 (8.2) 4.3 (2.4) 2.3 (1.5)
p = 0.001*
Duration (h)
25 mg 8.4 (3.8) 9.2 (5.5) 10.1 (8.0) 6.9 (7.7)
50 mg 8.8 (8.6) 6.0 (6.1) 5.3 (5.3) 5.9 (5.4)
75 mg 5.3 (4.7) 7.7 (6.3) 10.9 (2.6) 12.3 (8.0)
100 mg 7.9 (7.1) 6.4 (8.8) 7.3 (3.1) 8.0 (5.7)
p = 0.82
Severity (VAS)
25 mg 5.1 (1.2) 5.1 (1.9) 5.6 (1.7) 4.9 (0.8)
50 mg 6.3 (1.3) 6.0 (0.5) 5.1 (1.3) 5.8 (1.4)
75 mg 5.0 (1.5) 4.4 (1.4) 4.0 (1.4) 4.3 (1.4)
100 mg 5.7 (1.2) 5.8 (1.5) 4.8 (1.4) 4.8 (1.4)
p = 0.75
Each row denotes mean and (SD)
Each time point denotes headache diary data of the preceding 4-week
period
* Statistical significance (p \ 0.05)
 25 mg arm 
     N = 10 
50 mg arm 
      N = 10
75 mg arm 
       N = 10 
Excluded 
  N = 42 
100 mg arm 
      N = 10 
 Screened 
   N = 82 
       Headache diary for 4 weeks before randomization 
Return every 4 weeks for follow up (at week 4 and 8) 
End of study at week 12 
Fig. 2 Flow diagram showing protocol from screening to end of
study
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show that a low daily dose of 25 mg of topiramate was
equally effective as 50, 75 and 100 mg in reducing head-
ache frequency. Two early published studies on topiramate
prophylaxis have been conducted in the Western popula-
tion. The first study [1] assessed topiramate against placebo
had found responder rates (50% reduction in headache
frequency) at 39% (50 mg/day), 49% (100 mg/day) and
47% (200 mg/day). However, it is comparable to our study
only for headache days, which were significantly reduced
for the 100 and 200 mg/day groups only. Another study
[2], employing a similar placebo-controlled protocol,
reported fairly similar findings. However, headache days
were not an outcome measure in this particular study.
Our findings can be compared to a previous study
comprising only Chinese patients [7], which found that
some patients appeared to benefit with doses as low as
25 mg/day, despite the mean dose being 80 mg for that
entire study which had employed a physician-led upward
dose titration depending on clinical response. As the end
results of this and our study were contributed by Chinese
patients, it is likely that differences in outcomes were due
to methodological variation. It should be noted that this
study was based on an escalating dose titration determined
by the treating physician depending on clinical response,
and concomitant prophylactic medications were allowed.
A second Asian study comprising Indian patients had
employed topiramate at 50 mg/day in a 4-week crossover
protocol [6]. In this study, topiramate was administered at a
fixed dose of 50 mg/day for only 4 weeks in a crossover
design with lamotrigine. These vital differences likely
contributed to incomparable findings with our study. To
this end, we are of the opinion that a fixed daily dosing
regimen would offer maximal practicality and convenience
both for the patient and the treating physician.
In terms of adverse events, paresthesia was by far the
most common. Its incidence was increased with higher
dosages, as previously noted in other studies [11, 12]. The
other adverse events occurred in fairly similar frequencies
across the four dosing groups. Hence, lower dosages may
potentially benefit patients in terms of better compliance as
a result of lower side effect occurrences. In addition, lower
dosage requirements may also imply cost savings for the
patient. As Asians display clinically different pharmacol-
ogy compared to Western patients, its is likely that our
findings of lower dosage requirements can be explained by
these physiological factors [13, 14].
In conclusion, our novel findings highlighting efficacy
of a fixed low dose of topiramate of 25 mg/day in migraine
prophylaxis also attest to advantages in terms of reduced
cost and favourable side effect profile.
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